Barclays Maintains Overweight on Arcus Biosciences, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Arcus Biosciences and raises the price target from $25 to $29.
October 25, 2024 | 5:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Peter Lawson has increased the price target for Arcus Biosciences from $25 to $29 while maintaining an Overweight rating, indicating a positive outlook for the stock.
The increase in price target from $25 to $29 by Barclays, along with maintaining an Overweight rating, suggests a positive sentiment from the analyst, which is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100